Lessons from clinical trials of alemtuzumab in multiple sclerosis

Multiple Sclerosis and Related Disorders

Volumn 2, Issue 2, 2013, Pages 92-95

  Chaudhuri, Abhijit ^a   Behan, Peter O ^b  

^a QUEEN S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA1A INTERFERON; NATALIZUMAB;

B LYMPHOCYTE; BRAIN ATROPHY; CHRONIC LYMPHATIC LEUKEMIA; CYTOKINE RELEASE SYNDROME; DISEASE EXACERBATION; DRUG APPROVAL; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; GRAFT REJECTION; HERPETIC STOMATITIS; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INFECTION; JOHN CUNNINGHAM VIRUS INFECTIOB; LYMPHOCYTE DEPLETION; MULTIPLE CYCLE TREATMENT; MULTIPLE SCLEROSIS; NOTE; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; SINGLE DRUG DOSE; SKIN FUNGAL INFECTION; THYROID DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VIRUS INFECTION;

EID: 84872799675     PISSN: 22110348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.msard.2012.08.005     Document Type: Note

References (19)

1. A.E. Anderson, A.R. Lorenzi, and A. Pratt Immunity 12 years after alemtuzumab in RA: CD5+ B-cell depletion, thymus-dependent T-cell reconstitution and normal vaccine responses Rheumatology 51 2012 1397 1406
2. P.O. Behan, A. Chaudhuri, and B.O. Roep Pathogenesis of multiple sclerosis revisited Journal of the Royal College of Physicians of Edinburgh 32 2002 244 265
3. A. Coles, M. Wing, and P. Molyneux Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis Annals of Neurology 46 1999 296 304
4. CAMMS223. Trial investigators. Alemtuzumab vs. interferon ß-1a in early multiple sclerosis. New England Journal of Medicine 2008; 359:1786-801.
5. M.R. Clatworthy, E.F. Wallin, and D.R. Jane Anti-glomerular basement membrane disease after alemtuzumab New England Journal of Medicine 359 2008 768 769
6. A.J. Coles, E. Fox, and A. Vladic Alemtuzumab more effective than interferon ß-1a at 5 year follow-up of CAMMS223 clinical trial Neurology 78 2012 1069 1078
7. A. Chaudhuri Lessons for clinical trials from natalizumab in multiple sclerosis British Medical Journal 332 2006 416 419
8. M. Cossburn, A.A. Pace, and J. Jones Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort Neurology 77 2011 573 579
9. A. Chaudhuri, and P.O. Behan Multiple sclerosis is not an autoimmune disease Archives of Neurology 61 2004 1610 1612
10. G. Desoubeaux, C. Caumont, and C. Passot Two cases of opportunistic parasite infections in patients receiving alemtuzumab Journal of Clinical Pathology 65 2012 92 95
11. H.H. Fundenberg Are autoimmune diseases immunologic deficiency states? R.A. Good, D.W. Fisher, Immunobiology: Current Knowledge of Basic Concepts in Immunology and Their Clinical Applications 1971 Sinauer Association Inc Stanford, Connecticut 175 183 [Chapter 18]
12. C.L. Hirst, A. Pace, and T.P. Pickersgill Campath 1-H treatment with aggressive relapsing remitting multiple sclerosis Journal of Neurology 255 2008 231 238
13. J. Lundin, A. Porwitt-MacDonald, and E.D. Rossman Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH 1-H) treatment as first line therapy for patients with chronic B-cell lymphocytic leukaemia Leukemia 18 2004 484 490
14. A. Loebermann, A. Winkelmann, and H.P. Hartung Vaccination against infection in patients with multiple sclerosis Nature Reviews Neurology 8 2012 143 151
15. S.I. Martin, F.M. Marty, and K. Fiumara Infectious complications associated with alemtuzumab use in lymphoproliferative disorders Clinical Infectious Diseases 43 2006 16 24
16. M. Muzza, D. Degl'Innocenti, and C. Colombo The tight relationship between autoimmune thyroid cancer, autoimmunity and inflammation: clinical and molecular studies Clinical Endocrinology 72 2010 702 708
17. A.Y. Peleg, S. Husain, and E.J. Kwak Opportunistic infections in 547 organ transplant receipients receiving alemtuzumab, a humanised monoclonal CD52 antibody Clinical Infectious Diseases 44 2007 204 212
18. A. Shirani, Y. Zhao, and M.E. Karim Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis Journal of the American Medical Association 308 2012 247 256
19. K.A. Thursky, L.J. Worth, J.F. Seymour, H.M. Prince, and M.A. Slavin Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab British Journal of Haematology 132 2005 3 12